Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/309% above fair value
$1.77−0.05 (-3.01%)
Close on Nov 18, 2026Market cap $271.84MP/E –Yield –
Editas Medicine free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Editas Medicine's free cash flow for the twelve months ending Jun 30, 2026 was -$120.55M. For fiscal 2025 it was -$165.85M. The highest annual figure on record is -$6.87M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$165.85M | – |
| FY2024 | Dec 31, 2024 | -$219.11M | – |
| FY2023 | Dec 31, 2023 | -$136.90M | – |
| FY2022 | Dec 31, 2022 | -$181.47M | – |
| FY2021 | Dec 31, 2021 | -$171.78M | – |
| FY2020 | Dec 31, 2020 | -$187.01M | – |
| FY2019 | Dec 31, 2019 | -$46.84M | – |
| FY2018 | Dec 31, 2018 | -$50.46M | – |
| FY2017 | Dec 31, 2017 | -$11.48M | – |
| FY2016 | Dec 31, 2016 | -$53.74M | – |
| FY2015 | Dec 31, 2015 | -$6.87M | – |
| FY2014 | Dec 31, 2014 | -$9.87M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$50.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$51.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$60.56M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.70M | – |
| Q2 FY2023 | Jun 30, 2023 | -$40.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$37.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$42.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$48.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$51.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.43M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.13M | – |
| Q2 FY2021 | Jun 30, 2021 | -$41.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$41.48M | -205.4% |
| Q3 FY2020 | Sep 30, 2020 | -$56.59M | – |
| Q2 FY2020 | Jun 30, 2020 | -$32.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$56.24M | – |
| Q4 FY2019 | Dec 31, 2019 | $39.33M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.13M | – |
| Q2 FY2019 | Jun 30, 2019 | -$27.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.72M | – |
| Q4 FY2018 | Dec 31, 2018 | -$88.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.78M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.12M | – |
| Q1 FY2018 | Mar 31, 2018 | -$23.47M | -133.9% |
| Q4 FY2017 | Dec 31, 2017 | -$25.36M | – |
| Q3 FY2017 | Sep 30, 2017 | -$28.73M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.52M | – |
| Q1 FY2017 | Mar 31, 2017 | $69.14M | – |
| Q4 FY2016 | Dec 31, 2016 | -$14.35M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.75M | – |
See a number that looks wrong?